SecBot SecBot
PRESS-RELEASE ·Filed Nov 6, 2026

PHAR

Pharming Group N.V.
BULLISH
Impact 6/10
Horizonmonths Processed11d 1h ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Monitor UK NHS reimbursement and access timelines for the pediatric indication; watch for similar pediatric label expansions in other geographies (US already approved for 4-11). The small patient population limits revenue upside, but the approval validates the drug's profile and supports broader international expansion.

DirectionBullish
Confidencehigh
Horizonmonths

Joenja

▲ Bullish Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercializing (first FDA approval March 2023). Label expansion for children 4-11 approved September 2026 with new doses available October 2026. EU launch starting Germany Q3 2026.
Next catalyst
None dated

What to watchJoenja's commercial ramp is the key story, watch quarterly Joenja revenue growth, EU launch uptake (starting Germany Q3 2026), and the pending sNDA for lower-weight pediatric patients (13kg to <27kg) submitted July 30, 2026. Phase 3 topline data for ages 1-6 (trial NCT05693129, primary completion July 2026) and Phase 2 CVID data (expected Q4 2026) are potential catalysts. The stock's 52-week low of $9.62 vs. analyst mean target of $34.35 suggests deep value if Joenja execution holds, but the company also faces headwinds from RUCONEST decline and recent revenue guidance cuts.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$12.29
T+0 close · Nov 6, 2026 · via day close
Latest settled
+2.52%
T+5 · $12.60
Vs SPY
−0.07%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $12.29entry
  2. T+1 · 8d ago +7.08%α +4.71% · $13.16
  3. T+5 · 4d ago +2.52%α −0.07% · $12.60
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharming announced UK MHRA approval extending Joenja (leniolisib) to children aged 4-11 weighing at least 27 kg with APDS, making it the first approved treatment for this pediatric group in the UK. The expansion builds on the existing indication for adults and adolescents 12+, with availability expected in February 2027. This is a positive regulatory milestone for a rare disease drug with limited competition, but the addressable patient population is very small (1-2 per million worldwide).

Key Facts

  • UK MHRA approved Joenja for children aged 4-11 weighing at least 27 kg with APDS
  • First treatment approved in the UK specifically for children with APDS
  • Approval supported by pediatric clinical program and MHRA-agreed Pediatric Investigation Plan
  • Joenja expected to become available to patients in February 2027
  • APDS affects approximately 1 to 2 people per million worldwide
  • Joenja already approved in US, UK, Australia, Israel, EU, Canada, South Korea for adults/adolescents 12+

Financial Impact

Expansion of addressable pediatric population in UK; APDS prevalence is 1-2 per million, so absolute patient numbers are small. Revenue contribution incremental to existing adult/adolescent franchise.

revenue

Risk Factors

  • Very small addressable patient population (1-2 per million) limits commercial impact
  • UK NHS pricing and access negotiations could delay revenue contribution
  • Competition from other PI3Kδ inhibitors or emerging therapies for APDS

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397310

Track record

18 reports on PHAR

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
  2. Nov 6, 202611d ago Press Release Bullish 6/10 Viewing Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
  3. Oct 27, 202620d ago 6-K Bullish 6/10 No price data
  4. Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
  5. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
  6. Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
  7. Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
  8. Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
  9. Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
  10. Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026